首页> 美国卫生研究院文献>other >First Pharmacophore-Based Identification of Androgen Receptor Down-regulating Agents: Discovery of Potent Anti-Prostate Cancer Agents
【2h】

First Pharmacophore-Based Identification of Androgen Receptor Down-regulating Agents: Discovery of Potent Anti-Prostate Cancer Agents

机译:首次基于药理学的雄激素受体下调剂的鉴定:有效的抗前列腺癌药物的发现。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) was developed for well known natural product androgen receptor down-regulating agents (ARDAs). The four common chemical features identified included: one hydrophobic group, one ring aromatic group and two hydrogen bond acceptors. This model served as a template in virtual screening of the Maybridge and NCI databases that resulted in identification of 6 new ARDAs (EC50 values 17.5 – 212 μM). Five of these molecules strongly inhibited the growth of human prostate LNCaP cells. These novel compounds may be used as leads to develop other novel anti-prostate cancer agents.
机译:针对众所周知的天然产物雄激素受体下调剂(ARDA),开发了定性3D药效团模型(基于共同特征的模型或Catalyst HipHop算法)。确定的四个常见化学特征包括:一个疏水基团,一个环芳基和两个氢键受体。该模型作为对Maybridge和NCI数据库进行虚拟筛选的模板,可识别出6种新的ARDAs(EC50值为17.5 – 212μM)。这些分子中有五个强烈抑制人前列腺LNCaP细胞的生长。这些新型化合物可用作开发其他新型抗前列腺癌药物的先导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号